Frantisek Bruha

Suggest Changes
Learn More
BACKGROUND Therapy by tyrosine kinase inhibitors (TKI) has become inevitable in treatment of advanced NSCLC. Mutations in EGFR and KRAS genes have been identified as the main potential predictive and(More)
  • 1